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ABSTRACT 
 
Background: H.I.V. infection usually requires several years to progress to A.I.D.S., which is the final stage of 
disease characterized by severe immuno-suppression. Clinically significant problems occur earlier in the natural 
history of H.I.V. infection, however, pulmonary disorders are found in all stages. Aim: Present study is mainly 
based to observe the prevalence of H.I.V.-1 infection and A.I.D.S. in pulmonary tuberculosis . Materials and 
methods: The present study of the prevalence of H.I.V-I infection in pulmonary tuberculosis was conducted on 52 
bacillary cases of pulmonary tuberculosis. 25 healthy, age, and sex matched control cases were taken. H.I.V-1 
infection was determined by testing the serum of the cases with Retro-Tek H.I.V.-1 E.L.I.S.A. method. Results: The 
majority of pulmonary tuberculosis cases were found in the age group 30-49. The disease was more common in 
males than in the females with M:F::2.5:1 ratio. At the time of admission into the study all the patients had 
complains of cough with sputum production. Majority had fever, loss of appetite, loss of weight, breathlessness. 
Other symptoms like haemoptysis, chest pain were also found in varying proportion. On clinical examination most 
of the patients had signs of infiltration, fibrocavity, fibrosis. About 2/3rd of the patients were radiologically far 
advanced. Moderately advanced lesions were found in rest of the cases. Where as only 6% had minimal lesions. The 
mode of transmission of HIV infection was probably heterosexual as none of the patients had previous history of 
homosexuality, blood transfusion, surgery. More number of HIV-1 seropositive  TB cases (25%) had serum for 
VDRL. significantly reactive than HIV-1 seronegative TB cases (17.5). Majority of HIV-1 seropositive TB cases 
gave history of promiscuity (75%) than the HIV-1 seronegative TB cases(47.5%). In the 52 cases of pulmonary 
tuberculosis selected for the study, 37 cases were non-reactive . The remaining 15 cases were found to be reactive 
and , of these initial reactive cases when test  was repeated 14 cases were found to be reactive again and were 
referred to as "repeatably reactive". When test was repeated in 12 of these 14 repeatably reactive cases 10 were 
found to be reactive again. Thus over all 10 cases were reactive for H.I.V-1 infection three times and 2 cases were 
reactive for two times. Conclusion: Anti-tuberculosis treatment was found to be equally efficacious in both HIV-1 
seropositive and seronegative pulmonary tuberculosis patients. Sputum smear conversion for A.F.B. bacilli was not 
influenced by HIV-1 infection. 
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Introduction 
 
The incidence of TB among newly diagnosed HIV-
infected children varies from 0.61 per 100 child-years 
(and a prevalence of 3%) in low burden countries like 
the United States[1,2]
 
 to 53.3 per 100 patient-years in 
high burden countries like South Africa[3]. 
Remorselessly Human Immunodeficiency virus 
_______________________________ 
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 (H.I.V.) infection, finds and reveals the vulnerabilities 
in our system of medical care and our social, economic, 
and political structures. Issues surrounding Acquired 
Immunodeficiency Syndrome (A.I.D.S.) seem to 
Penetrate into nearly every sphere of human existence; 
scientific research, ethics, law, the prisons, the world of 
art, economics, international relations, and personal 
intimacy. All this and much more are affected. In a 
broad sense, A.I.D.S. & H.I.V. infection have served as 
stark reminders of how human existence is inextricably 
linked with natural forces. Physicians must be prepared 
to deal with the problems of H.I.V.-1 infection and 
A.I.D.S. on several levels. As this disease spreads into 
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new populations, it will be the rare health care 
professional indeed who will not care for the patients 
with H.I.V. infection. This increases the need to 
counsel anxious, perplexed, and angry family and 
loved ones; provide rational guidance and leadership 
for confused and frightened communities; deal with 
issues of infection control; and evaluate and implement 
new therapies and diagnostic techniques. There are 
many moving targets when we deal with H.I.V. 
infection and A.I.D.S. In a few months, new 
knowledge may make parts of it incorrect or outdated. 
There have been many major changes in the 
epidemiology of H.I.V. infection and its complications. 
Some of these, such as the current resurgence of 
tuberculosis, including disease due to resistant 
Mycobacterium tuberculosis, and the spread of H.I.V. 
infection from drug users to their sexual partners, have 
had major impact on public health. In the late 1970's 
physicians on the East and West Coasts of United 
States started caring for patients who presented with 
complications of severe immune-deficiency, but in 
whom a known cause of immuno-suppression could 
not be identified. These patients, sexually active 
homosexual men, presented with Kaposi's sarcoma, 
pneumocystis carinii pneumonia, oral and esophageal 
candidiasis, and other infections and neoplasia 
characteristic of severely depressed cell-mediated 
immunity[3,4]Soon after, similar complications were 
noted among intravenous drug users and subsequently 
among the recipients of the transfused blood and blood 
products, including haemophilia patients. This disease 
was subsequently called acquired immuno deficiency 
syndrome. It was found to be caused by infection with 
a newely identified virus human immunodeficiency 
virus. This virus, a human retrovirus, infects the T-
helper lymphocytes leading, over a period of years 
through mechanisms that are still being elucidated, to 
the depletion of these cells and the development of the 
progressive, severe, irreversible immune deficiency. 
Over the pass 10 years, infection with this virus has 
spread throughout the world and has produced the 
current pandemic of A.I.D.S. H.I.V. infection usually 
requires several years to progress to A.I.D.S., which is 
the final stage of disease characterized by severe 
immuno-suppression. Clinically significant problems 
occur earlier in the natural history of H.I.V. infection, 
however, pulmonary disorders are found in all stages. 
The incidence of tuberculosis is rising significantly in 
those areas where dual H.I.V. and tuberculous 
infections are prevalent . Pulmonary tuberculosis 
differs from other H.I.V. related infections in that it is 
spread by respiratory route from human to human from 
both normal and immuno-compromised host. 
Furthermore, in H.I.V. infected patients, tuberculosis 
often presents with an a typical picture that confounds 
diagnosis. Tuberculin anergy is common, the chest 
radiograph is often a typical and there is a high 
incidence of extra-pulmonary and disseminated 
disease[5,6].Fortunately, even among H.I.V. immuno-
suppressed persons, tuberculosis is preventable and 
curable1. Control of the tuberculosis epidemic requires 
the early recognition and treatment of H.I.V. infected 
persons with tuberculous infection or disease and 
ensuring their compliance with therapy[7]. It also 
requires the institution and maintenance of strict 
environmental control measures in A.I.D.S. clinics, 
wards,and hospitals where H.I.V. immunosuppressed 
patients, who are at great risk of contracting 
tuberculosis, are recurrently exposed to each other. The 
risk of acquiring tuberculous infection (i.e. as 
documented by the development of a significant 
tuberculin skin reaction) and the risk of tuberculous 
infection progressing to disease is primarily related to 
the frequency and density of tuberculous bacilli in the 
air of the pe'rson's environment. The risk of 
tuberculous infection progressing to disease is related 
to the patients T-cell immune response. The World 
Health Organisation (W.H.O.) estimates 30 - 60% of 
adults in developing countries are infected with 
mycobacterium tuberculosis. In some developing 
countries, over half the population is infected by the 
time they reach adulthood
7
. In part of the Sub-saharan 
Africa 5 - 15% of the general urban population and 10 -
15% of sexually active urban young adults are thought 
to be infected with H.I.V. In those developing countries 
where H.I.V. infection is becoming prevalent (Asia and 
Africa) and tuberculous infection has long become 
endemic e.g. Sub-Saharan Africa, parts of Latin 
America and the Caribbean the incidence of 
tuberculosis, which is already high, will rise steeply, 
and the resources for tuberculosis control which are 
currently inadequate, will be strained even more[8].A 
rising incidence of tuberculosis has already been 
documented in Tanzania, Burundi, Uganda, Zaire, 
Abidjan and Malawi. At present in India about 10 
million persons are suffering with radiologically 
suspected pulmonary tuberculosis, of which, about 2.5 
million would be sputum positive cases. The number of 
deaths are estimated to be nearly 500,000 every year. 
The projection of W.H.O. with regards to H.I.V. 
infection and A.I.D.S. in Asia and Africa by 2000 A.D. 
suggest an extremely high prevalence of H.I.V. 
infection .
9
 It would be worth while to note the 
relationship between pulmonary tuberculosis and 
H.I.V. infection and the effect of the same on the 
overall prevalence of tuberculosis. Present study is 
mainly based to observe the prevalence of H.I.V.-1 
infection and A.I.D.S. in pulmonary tuberculosis. 
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Material and methods  
This study was undertaken in Bhaskar Medical 
College, Moinabad during the period from June 2012 
to November 2013. Material for the present study 
comprised of 52 bacillary cases of pulmonary 
tuberculosis admitted to the institution. Age and sex 
matched 25 healthy normal subjects without any 
evidence of pulmonary tuberculosis or any other 
infection in the past one year were taken as control 
group.  
Inclusion criteria: Patients clinically diagnosed and 
confirmed by the presence of A.F.B. in the sputum.  
Exclusion criteria: Patients suffering with diabetes 
mellitus and other similar diseases were excluded.  
 All the selected patients were hospitalized. The cases 
were subjected to meticulous history, thorough clinical, 
radiological and biochemical examination at the time 
of admission.  Routine investigations like urine 
examination, T.C., D.C., E.S.R., blood sugar, blood 
urea, serum creatinine were performed in all cases 
admitted into the study. Apart from above 
investigations all basic investigations were done like 
Liver function test, Sputum for AFB by Ziehl-Neilsen 
method, Direct smear for gram stain, Sputum for 
culture and sensitivity for pyogenic organisms , 
Mantoux test, V.D.R.L.examination, and  X-ray chest 
P.A.view was taken.Retro-tek HIV-1 ELISA test  was 
done to confirm HIV . It is  enzymed linked immuno-
sorbent essay for the detection of antibodies to human 
immuno-defeciency virus type-1 in the human serum or 
plasma. The presence of circulating anti-bodies 
indicates that the individual had prior exposure to 
HIV1 viral proteins. Determination of mean of 
negative control,  the two separate ELISA reading of 
negative control are added together the result is divided 
by two (giving average absorbents) Determination of 
mean of positive control. The two separate ELISA 
readings & absorbents are of positive control of similar 
e added together and the result is divided by two. The 
value obtained represents the mean of positive control . 
Cut off value the cut off value is determined by 
dividing the mean of positive control by two. The 
resulting value is considered the cut off value between 
nonreactive and reactive readings. Interpretation of 
results is by Specimen with absorbents values equal to 
or less than the cutoff value are considered nonreactive 
and retrotek hiv ELISA is considered negative for 
antibodies to HIV. Further testing is not required.  
Specimens with absorbent values greater than cutoff 
value are considered reactive (initial reactive). The 
original sample is retested . Initially reactive specimens 
which do not react in the repeat test are considered 
negative for HIV. If the specimen is repeatable reactive 
the probability that anti-bodies to HIV are present is 
high. In most settings it is appropriate to investigate 
repeately reactive specimens by addtional more 
specific test. After the above investigations all the 
patients were put on tab Ethambutol, Tab INH, Cap 
Rifamycin and Tab Pyrazinamida. The drugs were 
changed during the course of study in some patients   
due to development of toxicity. 
Results 
Table 1:  Demographic Distribution 
Age in Yrs No. of controls Percentage No. of Patients Percentage 
10-19 0 0 3 5.8 
20-29 5 20 11 21.2 
30-39 9 36 20 38.4 
40-49 7 28 9 17.3 
50-59 4 16 5 9.6 
60-69 - - 4 7.7 
SEX     
Females 7 28 15 28.85 
Males 18 72 37 71.15 
 
The majority of pulmonary tuberculosis cases were found in the age group 30-49. The disease was more common in 
males than in the females with M:F::2.5:1 ratio.  
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Table 2: Distribution of symptoms in patients 
Symptoms No. of Patients Percentage 
Cough with or without expectoration 52 100 
Chest Pain 24 46.15 
Haemoptysis 15 28.85 
Fever 47 90.40 
Loss of appetite 42 80.90 
Loss of Weight 32 61.50 
Palpitaions 7 13.50 
SOB 32 61.50 
Giddiness 19 36.50 
Hoarseness of voice 3 5.80 
Malaise 14 26.90 
Joint Pains 3 5.80 
Others   
Skin Rash 2 3.80 
Back Ache 1 1.90 
Parathesias 6 11.50 
Signs   
General Examination Anemia 30 57.7 
Icterus 1 1.9 
Lymphadenopathy 5 9.6 
Thickened nerves 11 21.2 
Clubbing 24 46.1 
Pedal Oedema 8 15.4 
Others 7  
J V P 1 1.9 
Respiratory system infiltrative 25 48.1 
Cavitary 19 36.5 
Fibrotic 16 30.8 
Pleuritic 2 3.8 
Normal 2 3.8 
 
At the time of admission into the study all the patients had complains of cough with sputum production. Majority 
had fever, loss of appetite, loss of weight, breathlessness. Other symptoms like haemoptysis, chest pain were also 
found in varying proportion. On clinical examination most of the patients had signs of infiltration, fibrocavity, 
fibrosis.  
 
Fig 1: Distribution of radiological extent of disease 
6% 
29% 
65% 
Extent of lesions 
Minimal Moderately Advanced Far Advanced
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About 2/3rd of the patients were radiologically far advanced. Moderately advanced lesions were found in rest of the 
cases. Where as only 6% had minimal lesions.  
Table  3: Prevalence of HIV-1 patients and controls 
  Reactive  Non Reactive 
 No. of Patients % No of Patients % 
No. of Patients 52 11 23.1 40 76.9 
No. of Controls 0 0 25 100.0 
Correlation of Age distribution  
10-19 0 0 3 7.5 
20-29 5 41.7 6 15 
30-39 2 16.7 7 45 
40-49 2 16.7 4 10 
50-59 1 8.3 4 10 
60-69 2 16.7 2 5 
Correlation of sex distribution 
Female 6 50 9 22.5 
Male 6 50 31 77.5 
he majority of pulmonary tuberculosis cases were found in the age group 30-49 
Table  4: Correlation of symptoms and signs in HIV-1 reactive and non-reactive categories 
Symptoms HIV-1 Reactive  Non- Reactive  
 No of Patients % No. of Patients % 
Cough with expect 12 100 40 100 
Chest pain 5 41.6 19 47.5 
Haemoptysis 4 33.3 9 22.5 
Fever 12 100 35 87.5 
Loss of appetite 10 83.3 32 80 
Loss of Weight 9 75 23 57.5 
Palpitations 2 16.7 5 12.5 
SOB 9 75 23 57.5 
Giddiness 9 75 24 60 
Malaise 4 33.3 10 25 
Joint Pains - - 3 7.5 
Others 
Skin Rash 
- - 1 2.5 
Back Ache - - 6 15 
Parasthesia 1 8.3 - - 
Night Sweats 2 16.7 - - 
Duration of Symptoms 
0-2 Months 1 8.3 4 10 
3-5 Months 2 16.7 5 12.5 
6-8 Months 5 41.6 12 30 
9-12 Months 1 8.3 9 22.5 
13-18 Months 0 0 1 2.5 
19-24 Months 2 16.7 4 10 
2-3 Years - - 3 7.5 
3-4 Years - - - - 
4-5 Years - - 3 7.5 
Signs 
General examination 
Anemia 
9 75 1 52.5 
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Icterus 0 0 1 2.5 
Lymphadenopathy 1 8.3 4 10 
Thickended Nerves 1 8.3 10 25 
Clubbing 4 33.3 20 50 
Pedal Edema 3 25 5 12.5 
Other JVP 2 16.7 5 12.5 
Neck Stiffness 1 8.3 - - 
Respiratory system 
Infiltrative 
7 58.3 18 45 
Cavitary 4 33.3 15 37.5 
Fibritic 2 16.7 14 35 
Pleuritic - - 2 5 
Normal 1 8.3 1 2.5 
 
Table  5:Correlation of radiological extent of disease in HIV-1 reactive and non-reactive categories 
Radiological extent  HIV 1 Reactive  Non Reactive 
 No. of Patients % No. of Patients % 
Minimal 1 8.3 2 5 
Moderately Advanced 6 50 91 22.5 
Far Advanced 5 41.7 29 72.5 
 
Table  6: Correlation of variables reaction in HIV-1 sero + ve and sero  - ve 
 
Tuberculin skin reaction  SERO + VE  SERO - VE 
 No of patients % No of patients % 
0-4 mm 2 16.7 11 27.5 
5-9 mm 1 8.3 4 10 
10 mm 9 75 25 62.5 
Modes of transmission 
Promiscuity 9 75 19 47.5 
Surgery - - 2 5 
H/O Blood Transfusion - - 2 2 
Past treatment history 9 75 15 37.5 
V D R L 3 25 7 17.5 
BCG Scars 3 25 12 30 
Mortality 1 8.3 2 5 
 
The mode of transmission of HIV infection was probably heterosexual as none of the patients had previous history 
of homosexuality, blood transfusion, surgery. More number of HIV-1 seropositive  TB cases (25%) had serum for 
VDRL. significantly reactive than HIV-1 seronegative TB cases (17.5). Majority of HIV-1 seropositive TB cases 
gave history of promiscuity (75%) than the HIV-1 seronegative TB cases(47.5%).  
Table 7: Correlation of drug reactions in HIV-1 sero + ve and sero - ve categories 
Drug Reaction  SERO+VE  SERO-VE 
 No. of Patients % No of Patients % 
Nausea 2 16.7 10 25 
Vomiting 2 16.7 7 17.5 
Giddiness 1 8.3 8 20 
Paraesthesia 3 25 11 27.5 
Jaundice 1 8.3 - - 
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Rash 1 8.3 - - 
Arthralgia  - 1 2.5 
Convulsions - - 1 2.5 
Paraesthesia is most common drug reactions seen in study 
 
Fig 2: Status of sputum after chemotherapy 
In the 52 cases of pulmonary tuberculosis selected for 
the study, 37 cases were non-reactive . The remaining 
15 cases were found to be reactive and , of these initial 
reactive cases when test  was repeated 14 cases were 
found to be reactive again and were referred to as 
"repetably reactive". When test was repeated in 12 of 
these 14 reputably reactive cases 10 were found to be 
reactive again. Thus over all 10 cases were reactive for 
H.I.V-1 infection three times and 2 cases were reactive 
for two times. 
Discussion  
Tuberculosis is a major public health problem in the 
developing countries of the world today. 
Approximately 10 million people are suffering from 
pulmonary tuberculsis in our country. No authentic 
information about the prevalence of tuberculoses in 
India was available before the National Sample Survey 
carried out between 1955-1957 (I.C.M.R 1958) 
According to the National Sample Survey the finding 
are Prevalence rate of active and probably active 
tuberculosis varies from 13 -25/ thousand aged 5 yrs 
and above. Rate of bacteriologically positive cases per 
thousand varies from 2 - 8. Prevalence is lower in 
females than males especially in age group 35 years 
and above[10].After this study, several epidemiological 
studies have been conducted in small group of persons 
they have  large confirmed the findings of National 
Sample Survey. The AIDS epidemic has already had a 
profound impact on Tuberculosis morbidity in the 
U.S.A[11] HIV sero prevalence rates reported in the 
African patients among tuberculosis patients are; 
Zaire73 (33 - 36%), Uganda (30%), Cote- D'Ivoire 
(24%), Burundi (58%), Kenya (16%). In the present 
study the reported prevalence of HIV sero positivity 
among Tuberculosis patients is 23.1%. The difference 
in the prevalence of HIV sero positivity among the 
T.B. patients are probably related to difference in their 
back ground prevalance of tuberculous infection. Thus 
it appears that if a person is tuberculous infected and 
becomes immuno suppressed from HIV infection he 
has an extermely high risk of developing clinically 
active tuberculosis. Several lines of evidence support 
the hypothesis that A.I.D.S., and HIV infection are 
involved in the secular trends noted in tuberculosis 
prevalence. First, since other immuno supperssive 
disorders are associated with an increased risk of 
developing clinically apparent tuberculosis. It is 
biologically plausible that the severally compromised 
immunity secondly to AIDS and HIV infection will 
favour activation of pre-existing latent tuberculous 
infection. Secondly, the states and cities with largest 
AIDS cases has had the largest T.B. increased of any 
0
5
10
15
20
25
30
35
40
4th week 8th week
N
u
m
b
e
r 
o
f 
p
at
e
in
ts
 
Sputum status after 
chemotherapy 
 
Asian Pac. J. Health Sci., 2016; 3 (4):155-164                                        e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ___________________________________________________________________________________________________________________________________________ 
Bajaj and Saboo             ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(4): 155-164 
www.apjhs.com      162 
 
state or city[12].In the present study majority of the 
patient belonged to age group 30 to 39 (38.4%) the 
number of patients in the age group 30 to 49 is (55.7) 
of the total number of cases. Among the HIV sero 
negative cases of pulmonary tuberculosis the majority 
of patients belonged to age group 30 - 39 (45%) where 
as in the HIV sp cases of pulmonary tuberculosis 
majority belonged the age group of 20 - 29 (41.7%). 
This could be due to the increased sexual actvity in this 
age group. The sex distribution in the present study is 
similar to those of others who have confirmed the 
finding of National Sample Survey. Holmes CB et.al
13
 
has stated that the prevalence as well as incidence of 
disease are higher among males than females, with 
male to female ratio varying from 3:1 to 5:1. The male 
to female ratio in present study was 2.5:1. The Sex 
Distribution among the HIV sero negative case of 
pulmonary tuberculosis was similar to that of National 
Sample Survey. But the ratio in HIV sero postive case 
of pulmonary tuberculosis was 1:1.In our study the 
pulmonary tuberculosis cases were investigated for 
HIV serology using Retro-Tek HIV-1 ELISA method 
which detect anti bodies against the various HIV 
proteins. Out of the 52 cases 37 cases where found to 
be non-reactive at the initial testing. The rest of the 
patients i.e., 15 were declared 'Reactive'134. On the 
repeating the ELISA test on the 15 reative patients 14 
were `repetably reactive' . When ELISA test was 
repeated in 12 of these repetably reactive cases 10 were 
again found to be 'Reactive'. Confirmatory test like 
'Western Blot' is to be done to confirm all the cases. 
Braitstein P et al study of pulmonary tuberculosis have 
found cough (96%), fever (86%), weakness & loss of 
weight (80%), chest pain (71%), loss of appetite (65%), 
and haemoptysis (30%) of cases. In the present study 
cough with sputum production (100%) fever (90%) 
loss of appetite (80%) weakness & loss of weight 
(61%) are in co-relation with the study of Singh. 
Among the HIV sero positive cases of pulmonary 
tuberculosis fever (100%), cough with sputum 
production (100%), loss of weight (75%), loss appetite 
(83%) and haemoptysis (33%) are also in corelation 
with finding . In the present study HIV sero positive 
patient of pulmonary tuberculosis (80%), came with 
the complains of symptoms earlier than HIV sero 
negative case of pulmonary tuberculosis (50%) in the 
first 8 months. Hopewell PC 
15
 have described the 
symptoms of HIV sero postive pulmonary tuberculosis 
as non- specific presenting with cough, fever, night 
sweats, malaise, loss of appetite, loss of weight, 
haemoptysis, pleuritic chest pain and shortness of 
breath. Minor variations noted the present study 
between sero postive and sero negative pulmonary 
tuberculosis can be due to extensive nature of diease. 
None of the selected patients presented with any other 
system involvement or with clinical features like 
herpes, thrush suggesting severe immuno suppression. 
In the present study patient of HIV sero positive 
pulmonary tuberculosis presented with physical signs 
of infiltration (58.3%), cavity (33.3%), fibrosis 
(16.8%). Among the HIV sero negative cases of 
pulmonary tuberculosis presented with infiltration 
(45%) cavity (37.5%), fibrosis (35%). The reason for 
more infiltrative and less fibrotic lesion in HIV sero 
positive case could be due to decreased immunity. 
Havlir DV et.al described that severe & progressive 
pulmonary tuberculosis may fail to produce any 
symptom that can be recoginsed by either the patient or 
the physican[16]. When the patient do develop 
symptoms, the disease is likely to be advanced. In the 
present study 65% of the patients had far advanced 
lesion and (29%) had moderately advanced lesion. 
Only (6%) had minimal lesion, the reason being as this 
diease is common in low socio-economic status they 
neglect the symptoms, in the early stage of the diease 
and unless they are very sick they do not come for 
hospitaliasation. This, finding goes against the finding 
of National Sample Survey, in which majority had 
moderately advanced lesion. The reason is that here the 
cases were taken from hospitalised patients, whereas 
that study was undertaken in general population. The 
findings in the present study corroborates with findings 
of Khanna[17]
 
 who observed far advanced lesion in 
(87.5%) in hospitalised pulmonary tuberculosis cases. 
In the present study 2 out of 12 cases of HIV sero 
positive pulmonary tuberculosis presented with 
INFRA-HILAR pulmonary tuberculosis lesion. These 
atypical findings corrobrates with the findings of 
Debnath J, et al[18]who have reported atypical 
radiographic presentations of pulmonary tuberculosis 
in HIV sero positive cases (20% to 45%). According to 
the global summary 1991 reported by C.D.C., HIV 
transmission commonly occur with sexual intercourse 
(75%) of which (60%) in vaginal, (15%) in anal. I.V.-
drug abuse, perinatal transmission occur in (10%) each 
andblood transfusion responsible for (5%). In the 
present study all the HIV sero positive cases of 
pulmonary tuberculosis were hetero-sexual with none 
being homo-sexual, none of them were I.V.-drug 
abusers and no one was transfused blood. In the present 
study the higher incidence of promiscuity (75%) was 
seen among HIV sero positive cases of pulmonary 
tuberculosis, whereas only (47.5%) gave history of 
promiscuity in HIV sero negative cases of pulmonary 
tuberculosis. Serum for V.D.R.L., was significantly 
reactive in 25% HIV sero positive cases of pulmonary 
tuberculosis, whereas only (17.5%) of HIV sero 
negative cases of pulmonary tuberculosis has 
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significant V.D.R.L., reactivity.According to literature  
the tuberculin skin reaction of more than 10mm 
induration was similar for of HIV sero positive and 
sero negative pulmonary tuberculosis cases. In the 
present study the tuberculin skin reaction (1 PPD) was 
found to be more than 10mm induration almost equally 
in HIV sero positive (75%) and HIV sero negative 
(62.5%), cases of pulmonary tuberculosis[19].
 
In the present study the sputum conversion by smear at 
the end of second month in the HIV sero positive 
pulmonary tuberculosis cases is (100%) which is 
almost identical to the finding of the above studies. The 
HIV sero negatives cases of pulmonary tuberculosis 
also showed 100% sputum conversion by smear. The 
regimen used i.e., 2 EHRZ/4 HR is in accordance with 
the recommendations of American Thoracic Society. 
The 100% response seem in both HIV sero positive and 
HIV sero negative is similar to the studies 
reported[18].The treatment regimen of 2 EHRZ/ 4 HR 
was selected to avoid the emergence of resistant 
tubercle bacilli. Injection streptomycin was avoided in 
the study to reduce the risk of transmission of HIV 
infection from patient to patient. The conventional drug 
regimens of R1 to R5 were not used for the fear of 
emergence of resitant tubercle bacilli. Due to drug 
toxicity treatment was changed to HE in two cases. 
Nausea occured in 16.7% in HIV sero positive cases 
and in 25% of sero negative pulmonary tuberculosis 
cases. The nausea was probably due to rifampicin for it 
disappeared after consuming rifampicin with food. 
Hepatitis occured in 16.7% of HIV sero positive 
patients whereas it was not seen in HIV sero negative 
cases. Hepatitis was probably due to rifampicin as it 
subsided after removal of rifampicin from the 
treatment. This is similar to findings Villarino ME
 
20
who reported 1/5th patient receving RH developing 
some kind of hepatic reaction. In India Parthasarathy 
et. al recorded jaundice in 8% patients on rifampicin 
therapy, Hepatitis occurred in 10% of patients with 
spinal tuberculosis, 16-39% of children with meningitis 
and 2-8% with pulmonary disease treated with rifampin 
and isoniazid, arising 1-6 months after starting therapy, 
more commonly in slow acetylators). 
Conclusions  
 Pulmonary tuberculosis is more prevalent in the age 
group 30-49 years. It is more prevalent in males than in 
females with a ratio of M:F::2.5:1.  Among the selected 
patients radiologically far advanced lesion was noted in 
2/3 rd cases.  On random selection of 52 
bacteriologically positive pulmonary tuberculosis 
patients 12 were found to be "repeatably positive" to 
RETRO-TEK H.I.V-1 E.L.I.S.A. test for detection of 
antibodies to H.I.V. proteins. Thus 23.1% 
seroprevalence was noted in pulmonary tuberculosis 
patients.  In H.I.V-1 seropositive pulmonary 
tuberculosis patients majority presented in 20-29 years 
age group with equal distribution between males and 
females (M:F::1:1).  Symptomatically and clinically 
both H.I.V. seropositive and seronegative pulmonary 
tuberculosis patients presented similarly. 2 out 12 cases 
of H.I.V-1 seropositive pulmonary tuberculosis patients 
presented with infra-hilar pulmonary tuberculosis.  
Anti-tuberculosis treatment with 2EHRZ+4HR was 
found to be equally efficacious in both H.I.V-1 
seropositive and seronegative pulmonary tuberculosis 
patients. Sputum smear conversion for A.F.B. bacilli 
was not influenced by H.I.V-1 infection . Transmission 
of H.I.V-1 infection is probably due to heterosexual 
mode of transmission with promiscuious social habits 
being a high risk factor. 
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